Radiopharmaceuticals for the palliation of painful bone metastases

American Journal of Hospice and Palliative Medicine

Volumn 22, Issue 1, 2005, Pages 41-46

  Reisfield, Gary M ^a   Silberstein, Edward B ^b   Wilson, George R ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Advanced cancer treatment; Bone metastases; Palliative medicine; Radiopharmaceutical

Indexed keywords

HYDROXYAPATITE; LEXIDRONAM SAMARIUM SM 153; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; STRONTIUM 89;

ACUTE LEUKEMIA; ANALGESIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HOSPICE; HUMAN; LEUKOPENIA; NEUTROPENIA; PALLIATIVE THERAPY; PATIENT SELECTION; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 13444292171     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910502200110     Document Type: Review

References (47)

1. Foley KM: The treatment of cancer pain. N Engl J Med. 1985; 313(2): 84-94.
2. Hortobagyi GN: Novel approaches to the management of bone metastases. Semin Oncol. 2003; 30(5 Suppl 16): 161-166.
3. Data Evaluation & Publication Committee of the North America Association of Cancer Registries, based on cases included in the combined rates of cancer in the United States, 1995-1999.
4. McEwan AJ: Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000; 10(2): 103-114.
5. Lewington VJ: A practical guide to targeted therapy for bone pain palliation. Nucl Med Commun. 2002; 23(9): 833-836.
6. Twycross RG, Fairfield S: Pain in far-advanced cancer. Pain. 1982; 14(3): 303-310.
7. Mercadante S: Malignant bone pain: Pathophysiology and treatment. Pain. 1997; 69(1-2): 1-18.
8. Nielsen OS, Munro AJ, Tannock IF: Bone metastases: Pathophysiology and management policy. J Clin Oncol. 1991; 9(3): 509-524.
9. Falkmer U, Jarhult J, Wersall P, et al.: A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol. 2003; 42(5-6): 620-633.
10. Ben-Josef E, Shamsa F, Williams AO, et al.: Radiotherapeutic management of osseous metastases: A survey of current patterns of care. Int J Radiat Oncol Biol Phys. 1998; 40(4): 915-921.
11. Janjan NA: Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals. Cancer. 1997; 80(8 Suppl): 1628-1645.
12. Li EC, Davis LE: Zoledronic acid: A new parenteral bisphosphonate. Clin Ther. 2003; 25(11): 2669-2708.
13. Kelly WK, Steineck G: Bisphosphonates for men with prostate cancer: Sifting through the rubble. J Clin Oncol. 2003; 21(23): 4261-4262.
14. Small EJ, Smith MR, Seaman JJ, et al.: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003; 21(23): 4277-4284.
15. Papatheofanis FJ: Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med. 1999; 40(9): 1420-1423.
16. Pons F, Fuster D: Under-utilization of radionuclide therapy in metastatic bone pain palliation. Nucl Med Commun. 2002; 23(4): 301-302.
17. Serafini AN: Therapy of metastatic bone pain. J Nucl Med. 2001; 42(6): 895-906.
18. Porter AT: The Silberstein article reviewed. Oncology. 2001; 15(2): 169-170.
19. Nair N: Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med. 1999; 40(2): 256-261.
20. Silberstein EB, Eugene L, Saenger SR: Painful osteoblastic metastases: The role of nuclear medicine. Oncology (Huntingt). 2001; 15(2): 157-63; discussion 167-70, 174.
21. Goddu SM, Bishayee A, Bouchet LG, et al.: Marrow toxicity of 33P-versus 32P-orthophosphate: Implications for therapy of bone pain and bone metastases. J Nucl Med. 2000; 41(5): 941-951.
22. Mertens WC, Filipczak LA, Ben-Josef E, et al.: Systemic bone-seeking radionuclides for palliation of painful osseous metastases: Current concepts. CA Cancer J Clin. 1998; 48(6): 361-374.
23. Silberstein EB: The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol. 1993; 20(3 Suppl 2): 10-21. Review.
24. Dickie GJ, MacFarlane D: Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol. 1999; 43(4): 476-479.
25. Pons F, Herranz R, Garcia A, et al.: Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med. 1997; 24(10): 1210-1214.
26. Turner SL, Gruenewald S, Spry N, et al.: Metastron Users Group: Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001; 84(3): 297-302.
27. Kraeber-Bodere F, Campion L, Rousseau C, et al.: Treatment of bone metastases of prostate cancer with strontium-89 chloride: Efficacy in relation to the degree of bone involvement. Eur J Nucl Med. 2000; 27(10): 1487-1493.
28. Lee CK, Aeppli DM, Unger J, et al.: Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol. 1996; 19(2): 102-107.
29. Kasalicky J, Krajska V: The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998; 25(10): 1362-1367.
30. Quilty PM, Kirk D, Bolger JJ: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994; 31(1): 33-40.
31. Porter AT, McEwan AJ, Powe JE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993; 25(5): 805-813.
32. McEwan AJ, Amyotte GA, McGowan DG, et al.: A retrospective analysis of the cost-effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun. 1994; 15(7): 499-504.
33. Malmberg I, Persson U, Ask A, et al.: Painful bone metastases in hormone-refractory prostate cancer: Economic costs of strontium-89 and/or external radiotherapy. Urology. 1997; 50(5): 747-753.
34. Atkins HL: Therapy of bone pain. In Harbert JC, Eckelman WC, Newman RD (eds.): Nuclear Medicine: Diagnosis and Therapy. New York: Thieme Medical Publishers, 1996.
35. Shah Syed GM, Maken RN, Muzzaffar N, et al.: Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun. 1999; 20(8): 697-702.
36. Silberstein EB, Elgazzar AH, Kapilivsky A: Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 1992; 22(1): 17-27.
37. Burnet NG, Williams G, Howard N: Phosphorus-32 for intractable bony pain from carcinoma of the prostate. Clin Oncol (R Coll Radiol). 1990; 2(4): 220-223.
38. Hellman RS, Krasnow AZ: Radionuclide therapy for palliation of pain due to osteoblastic metastases. J Palliat Med. 1998; 1(3): 277-283.
39. Anderson PM, Wiseman GA, Dispenzieri A, et al.: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002; 20(1): 189-196.
40. Laing AH, Ackery DM, Bayly RJ, et al.: Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991; 64(765): 816-22.
41. Dafermou A, Colamussi P, Giganti M, et al.: A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001; 28(7): 788-798.
42. Windsor PM: Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: Report of a single centre's 10-year experience. Clin Oncol (R Coll Radiol). 2001; 13(3): 219-227.
43. Piffanelli A, Dafermou A, Giganti M, et al.: Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group. Q J Nucl Med. 2001; 45(1): 100-107.
44. Schmeler K, Bastin K: Strontium-89 for symptomatic metastatic prostate cancer to bone: Recommendations for hospice patients. Hosp J. 1996; 11(2): 1-10.
45. Silberstein EB, Williams C: Strontium-89 therapy for the pain of osseous metastases. J Nucl Med. 1985; 26(4): 345-348.
46. Roque M, Martinez MJ, Alonso P, et al.: Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2003; (4):CD003347.
47. Blake GM, Zivanovic MA, McEwan AJ, et al.: Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986; 12(9): 447-54.